Skip to main content
. 2020 Feb 29;48(8):4480–4491. doi: 10.1093/nar/gkaa127

Figure 1.

Figure 1.

LncRNA HCP5 is down-regulated in GCs from patients with bPOI. (A) Microarray heatmap of differentially expressed lncRNAs between GCs from controls (n = 10) and bPOI patients (n = 10). (B) Volcano plot of differentially expressed lncRNAs between GCs from controls and bPOI patients. (C) Schematic representation of location of HCP5 and MSH5 in chromosome. (D) The expression level of HCP5 was validated by qRT-PCR in GCs from an independent cohort of controls (n = 22) and bPOI patients (n = 20). Ct values were normalized to GAPDH. Data are presented as the median ± interquartile range. **P < 0.01.Two-tailed Mann–Whitney U-test. (E) The mRNA level of HCP5 in 21-week fetal tissues was validated by qRT-PCR. The expression level in ovary was set as ‘1’. GAPDH was used as internal reference. (F) Subcellular localization of HCP5 was detected by RNA FISH assay in KGN, COV434 and SVOG cells. (G) Relative HCP5 expression levels in the cytoplasmic and nuclear fractions of KGN, COV434 and SVOG cells by qRT-PCR. Lamin B1 was used as nuclear control. GAPDH was used as cytoplasmic control.